Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation

by Altcheh J, Moscatelli G, Caruso M, Moroni S, Bisio M, Miranda MR, Monla C, Vaina M, Valdez M, Moran L, Ramirez T, Ledesma Patiño O, Riarte A, Gonzalez N, Fernandes J, Alves F, Ribeiro I, Garcia-Bournissen F. PLOS Neglected Tropical Diseases 2023, 17(5): e0010850. doi: 10.1371/journal.pntd.0010850

Summary: The recommended medication for Chagas disease is benznidazole, but there is limited information on its effectiveness in children, especially infants and neonates. The authors studied the pharmacokinetics of benznidazole in children aged from newborn to 12 years old in a trial in five paediatric centers in Argentina. They found that children had lower levels of benznidazole in their blood compared to adults receiving similar weight-adjusted doses. However, the treatment was highly effective and well-tolerated, with few side effects. All children who completed treatment cleared the parasites. These findings highlight the importance of understanding how benznidazole works in children, in order to provide the right dose and duration of treatment for successful recovery with minimal adverse drug effects. 

The post Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation first appeared on DNDi.

Ajude os pacientes negligenciados

Até o momento, desenvolvemos nove tratamentos para doenças negligenciadas, salvando milhões de vidas. Temos o objetivo de disponibilizar 25 novos tratamentos em nossos primeiros 25 anos. Você pode nos ajudar!

Organização internacional, sem fins lucrativos, que desenvolve tratamentos seguros, eficazes e acessíveis para os pacientes mais negligenciados.

DNDi Global

Entre em contato

DNDi pelo mundo

Apoie a DNDi

Faça uma doação!

Trabalhe conosco

Oportunidades

Exceto para imagens, filmes e marcas registradas que estão sujeitos aos Termos de Uso da DNDi, o conteúdo deste site está licenciado sob uma Licença Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License.